Resveratrol treatment reversed age-related free cholesterol accumulation in cerebellar membranes of SAMP8 mice, a validated Alzheimer's model. The polyphenol reduced HMG-CoA reductase levels in 5-month-old mice, indicating modulation of cholesterol synthesis, while increasing LDL receptor expression to enhance cholesterol trafficking. Additionally, resveratrol upregulated mitochondrial electron transport chain complexes in younger animals. This cerebellar focus represents a significant research pivot. While most Alzheimer's studies concentrate on hippocampus and cortex, emerging evidence shows the cerebellum's extensive connectivity makes it crucial for cognitive networks and early pathological changes. The cholesterol-mitochondrial connection is particularly compelling—brain cholesterol dysregulation precedes amyloid pathology, and mitochondrial dysfunction drives neurodegeneration. However, this remains early-stage research using an animal model with modest sample sizes. The age-dependent effects (benefits primarily in younger mice) suggest preventive rather than therapeutic potential. While promising for understanding resveratrol's neuroprotective mechanisms, translating these cerebellar cholesterol findings to human Alzheimer's prevention or treatment requires substantial additional research, including human trials and optimal dosing studies.